PMID- 18203344
OWN - NLM
STAT- MEDLINE
DCOM- 20080214
LR  - 20191110
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 66 Spec No 1
DP  - 2006
TI  - [Antihypertensive effects of nifedipine and changing for modified-release 
      formula].
PG  - 7-9
AB  - Nifedipine was initially developed as an anti-anginal drug, and it was Professor 
      Murakami who first reported its usefulness in the management of hypertension. 
      However, rapid decrease in blood pressure with immediate-release formulations of 
      nifedipine led to simultaneous increases in heart rate, presumably because of 
      reflex sympathetic activation, and a meta-analysis in the mid-1990s suggested an 
      increased incidence of serious adverse events (AEs) with short-acting Ca2+ 
      channel antagonists. Although subsequent reviews of the literature found little 
      scientific basis for increased serious AEs with short-acting Ca2+ channel 
      antagonists, this controversy led to the accelerated development of long-acting 
      preparations. Recent clinical research has found improved outcomes in 
      hypertensive patients receiving long-acting Ca2+ channel antagonist preparations 
      and reconfirmed the role of nifedipine as a first-line agent.
FAU - Kuwajima, Iwao
AU  - Kuwajima I
AD  - Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - I9ZF7L6G2L (Nifedipine)
SB  - IM
EIN - Drugs. 2007;67(13):1849
MH  - Antihypertensive Agents/*administration & dosage/*pharmacology
MH  - Delayed-Action Preparations
MH  - Humans
MH  - Nifedipine/*administration & dosage/*pharmacology
RF  - 8
EDAT- 2008/01/19 09:00
MHDA- 2008/02/15 09:00
CRDT- 2008/01/19 09:00
PHST- 2008/01/19 09:00 [pubmed]
PHST- 2008/02/15 09:00 [medline]
PHST- 2008/01/19 09:00 [entrez]
AID - 10.2165/00003495-200666991-00004 [doi]
PST - ppublish
SO  - Drugs. 2006;66 Spec No 1:7-9. doi: 10.2165/00003495-200666991-00004.